Allowed claims cover major features of pumping mechanism in FDA-cleared MODD1 productSAN DIEGO, CA / ACCESSWIRE / September 18, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" thanks to its user-friendly and affordable design, announced the issuance of U.S. Divisional Patent Application No. 17/968,599."The issuance of this patent and the associated claims represent a major step in our efforts to protect the intellectual property in the MODD1 pump platform," stated Jeb Besser, CEO of Modular Medical. "Some of the key features
-Proof of Concept Study in Rapid Acting GLP-1 to commence in October 2024 with data expected in November 2024-Pre-clinical study to explore use of MODD1 pump as a personalized delivery system for people who discontinue long-acting GLP-1 formulations-CEO to discuss further details of the program in Tribe Public Webinar on Wednesday, September 11 at 8:30 a.m. Pacific time SAN DIEGO, CA / ACCESSWIRE / September 11, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" thanks to its user friendly and affordable design, today announced
SAN DIEGO, CA / ACCESSWIRE / September 4, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology, today announced it will hold a conference call and webcast tomorrow, Thursday, September 5, 2024, at 8:30 a.m. Eastern Time to discuss the U. S. Food and Drug Administration ("FDA") clearance of its MODD1 pump, as well as next steps and milestones.Conference Call and Webcast InformationDate: September 5, 2024Time: 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time)Conference Call Number: 1-88
SAN DIEGO, CA / ACCESSWIRE / September 4, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology, today announced it will hold a conference call and webcast tomorrow, Thursday, September 5, 2024, at 8:30 a.m. Eastern Time to discuss the U. S. Food and Drug Administration ("FDA") clearance of its MODD1 pump, as well as next steps and milestones.Conference Call and Webcast InformationDate: September 5, 2024Time: 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time)Conference Call Number: 1-88
MODD1 is a patch pump for ALL adults with Type 1 and Type 2 diabetesDesigned to be simpler and more affordable to expand access to diabetes technology for previously underserved communitiesCommercial availability expected in early 2025 SAN DIEGO, CA / ACCESSWIRE / September 4, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology, today announced it has received U. S. Food and Drug Administration ("FDA") clearance to market and sell its MODD1 pump in the United States. With its comme
SAN DIEGO, CA / ACCESSWIRE / January 19, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced the premarket submission of its MODD1 next-generation insulin pump to the FDA for 510(k) clearance."This is an exciting milestone for the Company, as we seek to change the diabetes market. Almost 30 years after the introduction of the first insulin pump, more than three quarters of those who could benefit from wearing a pump do not wear one. It is our belief that our simplified design will encourage many "a
4 - Modular Medical, Inc. (0001074871) (Issuer)
4 - Modular Medical, Inc. (0001074871) (Issuer)
4 - Modular Medical, Inc. (0001074871) (Issuer)
8-K - Modular Medical, Inc. (0001074871) (Filer)
8-K - Modular Medical, Inc. (0001074871) (Filer)
10-Q - Modular Medical, Inc. (0001074871) (Filer)
4 - Modular Medical, Inc. (0001074871) (Issuer)
4 - Modular Medical, Inc. (0001074871) (Issuer)
4 - Modular Medical, Inc. (0001074871) (Issuer)
SC 13G - Modular Medical, Inc. (0001074871) (Subject)
SC 13D/A - Modular Medical, Inc. (0001074871) (Subject)
SC 13G/A - Modular Medical, Inc. (0001074871) (Subject)
Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced that it is set to join the Russell Microcap Index at the conclusion of the 2024 Russell indexes annual reconstitution, effective when the U.S. market opens on July 1, 2024.Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
Gainers Aesthetic Medical Intl (NASDAQ:AIH) shares moved upwards by 23.3% to $0.57 during Monday's after-market session. The market value of their outstanding shares is at $27.0 million. Harrow (NASDAQ:HROW) shares rose 13.5% to $13.7. The market value of their outstanding shares is at $484.7 million. As per the press release, Q1 earnings came out today. Vaxart (NASDAQ:VXRT) stock moved upwards by 12.19% to $0.92. The market value of their outstanding shares is at $162.6 million. The company's, Q1 earnings came out today. Modular Medical (NASDAQ:MODD) shares moved upwards by 7.77% to $1.94. The market value of their outstanding shares is at $60.1 million. Gossamer Bio (NASDAQ:GOSS) stoc
Gainers Avalo Therapeutics (NASDAQ:AVTX) shares moved upwards by 215.8% to $15.0 during Wednesday's after-market session. The market value of their outstanding shares is at $12.0 million. Fresh2 Group (NASDAQ:FRES) stock moved upwards by 5.26% to $0.6. The company's market cap stands at $14.2 million. Biora Therapeutics (NASDAQ:BIOR) shares rose 5.12% to $1.23. The company's market cap stands at $33.4 million. As per the news, the Q4 earnings report came out yesterday. Athira Pharma (NASDAQ:ATHA) stock rose 5.07% to $2.69. The market value of their outstanding shares is at $103.0 million. Clearside Biomedical (NASDAQ:CLSD) stock rose 4.79% to $1.75. The company's market cap stands at $1
SAN DIEGO, CA / ACCESSWIRE / June 3, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced that it is set to join the Russell Microcap Index at the conclusion of the 2024 Russell indexes annual reconstitution, effective when the U.S. market opens on July 1, 2024.Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalizatio
SAN DIEGO, CA / ACCESSWIRE / July 6, 2023 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), a development stage insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today announced the appointment of medical device industry leader Duane DeSisto to its board of directors. Mr. DeSisto was previously President, CEO and Director of Insulet Corporation, developers of the groundbreaking OmniPod Insulin Management System, before retiring in 2014."Duane brings more than 25 years of experience in the medical device industry and is a visionary business leader credited with the launch and transformatio
Schmid brings 40 years of experience in medical devices for drug delivery and diabetes management and a background in high-volume manufacturingSAN DIEGO, CA / ACCESSWIRE / July 26, 2022 / Modular Medical, Inc. (the "Company" or "Modular Medical")(NASDAQ:MODD) today announced that it has appointed industry veteran Kevin Schmid as its Chief Operating Officer. Mr. Schmid brings extensive operations and business development leadership experience in diabetes and drug delivery. As Vice President of Operations and Business Development at Insulet Corporation, he was instrumental in the development, manufacturing, and commercialization of wearable smart drug delivery pumps such as the Omnipod Diabete